Alaunos Therapeutics (TCRT) 10-K2019 FY Annual report

Filed: 2 Mar 20, 4:03pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Avg

New words: accuracy, administrationof, afund, alloTCR, amountof, andBeneficial, andscalable, andsubsequent, apotent, arepursuing, ArsenalBio, asControlled, astargeting, autoTCR, baseline, believeControlled, benchmark, bleeding, BMT, borrow, borrowing, buildout, cemiplimab, choice, Circuit, cleared, ClinicalDevelopment, combinationof, combinationwith, compensatory, compliant, conditionallyproduce, customary, de, deficiency, developingControlled, EGFR, encourageuse, expresshuman, expressionof, GMP, Gorilla, Hadfield, havetested, inBlood, inClinical, incompetent, incremental, indefinitely, indemnification, India, inScience, intravenously, Iovance, Istari, Karyopharm, lab, left, libraryof, lieu, Lyell, Main, manufacturedusing, match, matching, membrane, MRI, multifocal, multitude, nonfinancial, Northwest, Novocure, Obsidian, ofControlled, ofin, ofrecombinant, ofTCR, online, Optune, ourcontrolled, PACT, partly, PB, PBMC, PGEN, potentialof, PrincipalAccounting, productionof, proper, Protheragen, pseudoprogression, reevaluate, reliant, remanded, rolling, Sath, Satyavrat, Schematic, Shukla, sixty, sublicensee, subscription, substudy, surgical, survivein, swelling, Takeda, thata, thatControlled, thelowest, Therecombinant, thisway, titledBeneficial, titledProposal, tocause, todeliver, toevaluate, Torque, transcription, transcriptional, trialof, unifocal, unilaterally, unpatentable, unqualified, upheld, useof, usinga, vendor, VIE, withRegeneron, withSleeping, worse

Removed: aberrant, add, alive, amending, amortized, andStock, attestation, bifurcated, clinic, collateral, column, constructing, consume, dilution, diversity, dosed, double, engineer, escalation, evolving, executed, explore, favorably, feature, forin, hospital, importing, indibulin, Indonesia, inventory, issuable, Juno, landlord, LLP, Malaysia, nanosuspension, Neon, noncash, NY, organoarsenic, poster, predecessor, preliminary, proportion, pursued, redemption, representing, restatement, RSM, San, Singapore, structure, substance, subtenant, sufficiency, sustainedin, systemic, Thailand, titledStock, today, towardsin, underRule, vivopersistence, voting, York, Zealand

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

Associated TCRT transcripts

TCRT similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 23.1

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

We consent to the incorporation by reference in the Registration Statements (Nos. 333-129884, 333-134280, 333-142701, 333-160496, 333-167925, 333-185433, 333-199304, 333-220804, and 333-228291) on Form S-8 and Registration Statements (Nos. 333-134279, 333-141014, 333-161453, 333-162160, 333-163517, 333-166444, 333-174292, 333-177793, 333-201826, 333-229555 and 333-232283) on Form S-3 of ZIOPHARM Oncology, Inc. of our report dated March 2, 2020 relating to the financial statements of ZIOPHARM Oncology, Inc. and subsidiaries (the Company) and our report relating to the effectiveness of the Company’s internal control over financial reporting dated March 2, 2020, which report expresses an adverse opinion on the effectiveness of the Company’s internal control over financial reporting because of a material weakness, appearing in this Annual Report on Form 10-K of ZIOPHARM Oncology, Inc. for the year ended December 31, 2019.

/s/ RSM US LLP

Boston, Massachusetts

March 2, 2020